Esketamine's Role in Postoperative Care for Elderly CRC Patients

Esketamine's Impact on Postoperative Depression

A recent randomized controlled trial (RCT) published on April 21, 2026, in an unknown venue, has highlighted the potential benefits of esketamine in managing postoperative depression and anxiety among elderly colorectal cancer (CRC) patients. The study, registered under the Chinese Clinical Trial Registry (ChiCTR2300070763), involved 99 patients aged 65 and above who underwent CRC resection. Participants were divided into three groups receiving different postoperative patient-controlled analgesia (PCA) regimens: sufentanil with a saline placebo, sufentanil with esketamine at 1 mg/kg, and sufentanil with esketamine at 2 mg/kg.

Mechanism and Clinical Findings

Esketamine, an NMDA receptor antagonist known for its rapid antidepressant effects, was administered alongside sufentanil. The primary outcomes measured were anxiety and depression levels using the Hamilton Anxiety Rating Scale (HAMA) and Hamilton Depression Rating Scale (HAMD) at 24 and 72 hours postoperatively. Both esketamine groups exhibited significantly lower depression and anxiety scores compared to the control group, with no significant dose-dependent differences. The study also reported higher patient satisfaction in esketamine groups without an increase in adverse events or changes in pain control efficacy.

Implications for Postoperative Care Protocols

The findings suggest that esketamine could be integrated into postoperative care protocols for elderly CRC patients to improve psychological outcomes. This could lead to updates in clinical guidelines, emphasizing the importance of addressing mental health alongside physical recovery in postoperative care, particularly for vulnerable populations such as the elderly.

Risks and Considerations

While the study presents promising results, it is crucial to consider the broader implications and potential risks. The absence of dose-dependent differences in efficacy suggests that lower doses may be preferable, minimizing potential side effects. However, long-term effects and the impact of esketamine on other patient demographics remain unknown, necessitating further research.

Future Research Directions

This study opens avenues for future research to explore esketamine's role in other surgical populations and its long-term impact on mental health. Additionally, understanding the mechanisms behind its antidepressant effects could lead to more targeted therapies for postoperative depression.